TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
2.060
+0.020 (0.98%)
Jul 17, 2026, 4:00 PM EDT - Market closed
TherapeuticsMD Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.42 | 7.48 | 5.06 | 4.33 | 38.07 | 64.91 |
Cash & Short-Term Investments | 8.42 | 7.48 | 5.06 | 4.33 | 38.07 | 64.91 |
Cash Growth | 46.54% | 47.91% | 16.92% | -88.63% | -41.35% | -19.36% |
Other Receivables | 3.21 | 3.53 | 3.56 | 3.09 | - | - |
Total Trade Receivables | 3.21 | 3.53 | 3.56 | 3.09 | - | - |
Other Current Assets | 3.63 | 3.44 | 3.64 | 4.38 | 17.28 | 54.56 |
Total Current Assets | 15.26 | 14.45 | 12.26 | 11.8 | 55.35 | 119.47 |
Net Property, Plant & Equipment | 5.06 | 5.29 | 6.1 | 6.87 | 7.66 | 9.06 |
Other Intangible Assets | 3.67 | 3.76 | 4.32 | 6.1 | 6.94 | 7.14 |
Other Long-Term Assets | 13.59 | 14.16 | 16.14 | 18.54 | 20.51 | 33.8 |
Total Assets | 37.58 | 37.66 | 38.82 | 43.31 | 90.46 | 169.47 |
Accounts Payable | 0.02 | 0.38 | 0.26 | 0.03 | 2.16 | 3.37 |
Accrued Expenses | 2.23 | 1.74 | 2.13 | 3.13 | 18.85 | 13.34 |
Current Portion of Long-Term Debt | - | - | - | - | - | 188.27 |
Other Current Liabilities | 2.67 | 2.67 | 2.78 | 3.69 | 25.83 | 47.91 |
Total Current Liabilities | 4.91 | 4.79 | 5.17 | 6.85 | 46.84 | 252.89 |
Long-Term Leases | 4.82 | 5.12 | 5.54 | 6.53 | 7.37 | 8.06 |
Other Long-Term Liabilities | 0.87 | 0.87 | 0.74 | 0.64 | 1.11 | 2.14 |
Total Long-Term Liabilities | 5.7 | 6 | 6.29 | 7.17 | 8.48 | 10.2 |
Total Liabilities | 10.61 | 10.78 | 11.45 | 14.02 | 55.32 | 263.09 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 979.26 | 979.26 | 979.18 | 978.92 | 974.5 | 957.73 |
Retained Earnings | -952.3 | -952.39 | -951.82 | -949.64 | -939.36 | -1,051 |
Shareholders' Equity | 26.97 | 26.88 | 27.37 | 29.29 | 35.14 | -93.62 |
Total Liabilities & Equity | 37.58 | 37.66 | 38.82 | 43.31 | 90.46 | 169.47 |
Total Debt | 4.82 | 5.12 | 5.54 | 6.53 | 7.37 | 196.33 |
Net Cash (Debt) | 3.6 | 2.36 | -0.48 | -2.21 | 30.7 | -131.43 |
Net Cash Growth | 52.27% | - | - | - | - | - |
Net Cash Per Share | 0.31 | 0.20 | -0.04 | -0.21 | 3.28 | -16.51 |
Book Value | 26.97 | 26.88 | 27.37 | 29.29 | 35.14 | -93.62 |
Book Value Per Share | 2.33 | 2.32 | 2.37 | 2.81 | 3.75 | -11.76 |
Tangible Book Value | 23.31 | 23.12 | 23.05 | 23.19 | 28.2 | -100.77 |
Tangible Book Value Per Share | 2.01 | 2.00 | 2.00 | 2.22 | 3.01 | -12.66 |